Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Related to this article
The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
Advertisement
Advertisement
Trending on Urology Times
1
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
2
Altaviva™ Tibial Implant Is Reshaping UUI Therapy
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
5